Learn more
APhA needs your assistance to ensure you can effectively care for you patients. Reach out to your Member of Congress and Senators and ask them to take immediate action to provide adequate, appropriate, and fair payment for pharmacist consultations and services for prescribing Paxlovid.
Act now
We’re excited to announce the launch of the new APhA Learning Library! This new platform will make it easier than ever for you to get the education you need. Read about some key highlights of our new system.
APhA is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that result in improved workplaces, well-being, and ability to meet ethical obligations to patient safety.
Optimizing Diabetes Care With GLP-1 Receptor Agonist
JFPS 2022
APhA-ASP Midyear Regional Meetings
Tools and resources to support your practice
Access Now
APhA’s monthly Pulse on Practice and Policy Open Forum Series creates a platform where all of pharmacy can come together to share perspectives and be informed of key practices and policies impacting the profession.
An APhA member-only resource for pharmacists, pharmacy residents, student pharmacists, pharmacy technicians, and interprofessional health care team members involved in providing transitions of care (TOC) services.
An outline of the key steps to implementing monoclonal antibody therapy administration services in community settings.
View CEO Blog
A letter from Interim CEO Ilisa Bernstein, PharmD, JD, FAPhA, to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA), on the importance of pharmacists being allowed to prescribe oral COVID-19 treatments.
View all press releases
WASHINGTON, DC—Today the American Pharmacists Association (APhA) and the National Alliance of State Pharmacy Associations (NASPA) released the third installment of the Pharmacy Workplace and Well-being Reporting (PWWR) trends and findings report series.
View all news
New CDC data show that 19 states and 2 territories have at least 35% of residents with adult obesity. That figure is more than two times the number of states with high adult obesity prevalence recorded in 2018.
An NIH-backed study reported in 2 papers in the New England Journal of Medicine shows that the diabetes treatments insulin glargine and liraglutide more effectively maintain target blood sugar levels than sitagliptin or glimepiride when added to first-line metformin.